ACTRN12606000277549已完成未知
The application of anti-cyclic citrullinated peptide autoantibody (anti-CCP) and soluble HLA-DR tests to the detection of early rheumatoid arthritis (RA) in New Zealand patients.
isa Stamp0 个研究点目标入组 80 人开始时间: 2006年7月3日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Patients who have been assessed by a rheumatologist and deemed to have undifferentiated inflammatory arthritis defined as history, examination and laboratory findings suggesting an inflammatory disorder, but which are not diagnostic of or classifiable as a specific rheumatic inflammatory condition 2. willing and able to provide informed consent
排除标准
- •1. Presence of chronic infection or other severe concomitant medical illness or psychiatric disease.2. Pregnant or breast-feeding females and female subjects of child bearing age who are not practising medically approved methods of contraception.3. HIV positive patients4. History of drug abuse that would interfere with the ability to comply with the study protocol5. Patients with active, concomitant malignancies.
研究者
相似试验
尚未招募
Unknown
Correlation between Anti CCP autoantibody concentration and severity of Rheumatoid arthritis (Sandhiva)CTRI/2023/12/060765All India Institute of Medical Sciences Rajkot
进行中（未招募）
不适用
Aprepitant in the prevention of cisplatin-induced delayed emesis: a double-blind randomized study - Aprepitant for cisplatin-induced delayed emesisEUCTR2008-001339-37-ITAZIENDA OSPEDALIERA S. MARIA DI TERNI560
已完成
不适用
Evaluation of NAC for prevention of post ERCP pancreatitis: a prospective double blind randomized pilot studypost ERCP pancreatitis.other acute pancreatitisIRCT201008094545N1Ahwaz Jondi Shapur medical univercity100
已完成
3 期
The safety and efficacy of Aprepitant to the prevention of chemotherapy-induced nausea and vomitingIRCT20200819048455N1Iran University of Medical Sciences85
进行中（未招募）
不适用
Vaccination med peptider deriveret fra anti-apoptotiske proteiner i Bcl-2 familien, administreret i kombination med adjuvant (Montanide ISA-51) i relation til proteasomhæmmerbehandling af patienter med relaps af myelomatose.En fase I/ II undersøgelseMyelomatose med andet eller senere relaps af sygdommen.MedDRA version: 8.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2006-003619-29-DKOrganisation name was not entered40